"Many people with obesity suffer from co-morbidities," said Novo Nordisk's chief science officer Mads Krogsgaard Thomsen, in a statement. "Saxenda has the potential to help some of these people ...

the chemical name of another Novo Nordisk product, Saxenda. Analysts at Citi said Hims & Hers’ goal of $725 million of weight-loss revenue in 2025 was ambitious, given oral-drug sales just ...

Novo Nordisk has been accepted back into the fold. Two years after suspending Novo, the Association of the British ...

Researchers have criticised the UK drug industry trade association’s decision to restore Novo Nordisk’s membership despite the company being subject to ongoing regulatory breaches during its two year ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

As of now, the only drug approved for weight management in Ireland is an older Novo Nordisk medicine, called Saxenda. And it can be prescribed only in limited cases – for patients with a body ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket ... will now focus on oral-based solutions and liraglutide (Saxenda), which is also a Novo product. "We see our steady-state ...